Sanofi India

Shares of CDSL last closed at Rs 1,382, up 0.25 per cent, valuing the company at Rs 28,879 crore

The fall in the share price came after the pharmaceutical company reported a weak set of June quarter of financial year 2025 (Q1FY25) results.

Each member of Sanofi India holding 1 equity share in Sanofi India as on the Record Date i.e. June 13, 2024 shall entitled to receive 1 equity share of Sanofi Consumer Healthcare India.

Shriram Finance announced that board has approved the sale of its housing finance subsidiary Shriram Housing Finance to Warburg Pincus for Rs 4,630 crore

Novavax said it would co-commercialize its Covid-19 vaccine with French drugmaker Sanofi and develop new Covid-19-influenza combination vaccines using Novavax's Matrix-M adjuvant

Sanofi reported that in India, over 100 million individuals are grappling with type 2 diabetes and its associated complexities

Aiming for a "fair share" in the Indian pharmaceutical market, French drug major Sanofi plans to introduce new drugs and enhance localisation while expanding the reach of its existing brands through collaboration with domestic drug firms, according to a top company official. The company plans to enhance its presence in the diabetes segment and grow its consumer healthcare business after spinning it off into a new entity while also looking at local production of its various best-in-class products in India. In an interaction with PTI, Sanofi India Managing Director Rodolfo Hrosz stated that the company has embarked on a mission to prepare for an accelerated growth path in the country. "We believe we're under-represented (in India) and we see a significant opportunity right now and in the future as well. The potential of this market is phenomenal," he said. He further said: "We are seeking the route to be better represented ... with a fair share of the Indian pharmaceutical ...

Under the terms of this agreement, Dr Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands, including Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri and Adacel

Open to licensing, collaboration in anti-diabetes space

Cipla will leverage its extensive network to distribute Sanofi's CNS portfolio, including Frisium, a leading anti-epileptic drug

Collaboration aligns with Sanofi's growth strategy in India, named 'India for India', aims to accelerate growth across its pharmaceuticals, specialty care, consumer healthcare, and vaccines business

Sanofi shares trade at a 12 month forward price-to-earnings ratio of 11, a discount to AstraZeneca's 16 and global pharma index of 17, according to LSEG data

Drug firm Sanofi India on Thursday said its net profit increased by 2.5 per cent to Rs 123 crore for the second quarter ended on June 30, 2023. The company reported a net profit of Rs 120 crore in the April-June quarter of last year. Revenue from operations rose to Rs 706 crore in the period under review from Rs 699 crore in the same period last year, Sanofi India said in a regulatory filing. The company follows a January-December financial year. "The company has delivered a strong second quarter performance despite the National List of Essential Medicines (NLEM) impact," Sanofi India Managing Director Rodolfo Hrosz said. The company will continue to focus on driving further improvement in operating efficiencies while expanding the availability of its established and innovative products in India, he added.

'Our insulin portfolio today offers best-in-class insulin for better diabetes management'

Company says split will allow it to unlock business potential in pharmaceuticals and consumer healthcare

Stock to Watch today: Adani Enterprises Ltd., the flagship company of Adani Group, said on Wednesday that it will hold a board meeting on May 13 to consider fund raise via issuance of equity

Sanofi Consumer Healthcare India is expected to be listed on both the BSE and NSE, the company said in an exchange notification

With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon

Drug firm Sanofi India on Thursday reported a net profit of Rs 131 crore for the third quarter ended September 2022. The company had posted a net profit of Rs 530 crore in the July-September quarter of last year, the company said in a regulatory filing. The drug firm follows a January-December financial year. Revenue from operations stood at Rs 692 crore in the period under review. The same stood at Rs 754 crore in the corresponding period previous year. The company said the results of the September quarter were not comparable with the same quarter last year as it had transferred its nutraceuticals business to Universal Nutriscience, enabling a gain of Rs 489 crore.

The decline was largely on account of divestment of its nutraceutical business and a few key brands.